Peripheral neuropathies under Immune Checkpoint Inhibitors: A pharmacovigilance study

被引：0
|
作者：
Ewig, E. [1 ]
Fournier, D. [1 ]
Palassin, P. [2 ]
Cholle, C. [3 ]
Bihan, B. [1 ]
Lebrun-Vignes, B. [1 ]
机构：
[1] GH Sorbonne Univ, Dept Pharmacol, Ctr Reg Pharmacovigilance Pitie St Antoine, AP HP, Paris, France
[2] CHU Montpellier, Ctr Reg Pharmacovigilance, Serv Pharmacol Medicale & Toxicol, Montpellier, France
[3] CHU Bordeaux, Ctr Reg Pharmacovigilance, Serv Pharmacol Medicale, Pole Sante Publ, Bordeaux, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2023年 / 37卷
关键词：
immune checkpoint inhibitors; peripheral neuropathy; pharmacovigilance;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PS-043
引用
收藏
页码：117 / 118
页数：2
相关论文
共 50 条
  • [21] Adverse reactions of immune checkpoint inhibitors combined with angiogenesis inhibitors: A pharmacovigilance analysis of drug-drug interactions
    Ren, Xiayang
    Deng, Lei
    Dong, Xin
    Bai, Ying
    Li, Guohui
    Wang, Yanfeng
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2024, 38
  • [22] Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
    Ruggiero, Rosanna
    Fraenza, Federica
    Scavone, Cristina
    di Mauro, Gabriella
    Piscitelli, Raffaele
    Mascolo, Annamaria
    Ferrajolo, Carmen
    Rafaniello, Concetta
    Sportiello, Liberata
    Rossi, Francesco
    Capuano, Annalisa
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [23] Peripheral neuropathies after BRAF and/or MEK inhibitor treatment: A pharmacovigilance study
    Picca, Alberto
    Birzu, Cristina
    Berzero, Giulia
    Sanchez-Pena, Paola
    Gaboriau, Louise
    Vidil, Faustine
    Lenglet, Timothee
    Tafani, Camille
    Ricard, Damien
    Psimaras, Dimitri
    Bihan, Kevin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (11) : 4941 - 4949
  • [24] Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study
    Haeuser, Lorine
    Marchese, Maya
    Cone, Eugene B.
    Noldus, Joachim
    Bayliss, George
    Kilbridge, Kerry Laing
    Quoc-Dien Trinh
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (07) : 1310 - 1316
  • [25] Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases
    Rabbani, Syed Arman
    Khurana, Atul
    El-Tanani, Mohamed
    Arora, Mandeep Kumar
    Sharma, Shrestha
    Sridhar, Sathvik B.
    Dubey, Harikesh
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [26] Adverse reactions of immune checkpoint inhibitors combined with Proton pump inhibitors: a pharmacovigilance analysis of drug-drug interactions
    Ren, Xiayang
    Li, Lu
    Chen, Yiran
    Cui, Xiangli
    Wan, Rui
    Wang, Yanfeng
    BMC CANCER, 2024, 24 (01)
  • [27] Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review
    Nguyen, Lee S.
    Raia, Lisa
    Lebrun-Vignes, Benedicte
    Salem, Joe-Elie
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [28] Myositis associated with Immune Checkpoint Inhibitors: A pharmacovigilance study using the World Health Organization's adverse drug reactions database
    Ladhari, C.
    Nguyen, T.
    Maria, A.
    Palassin, P.
    Quantin, X.
    Lesage, C.
    Taieb, G.
    Ayrignac, X.
    Rullier, P.
    Lambotte, O.
    Guilpain, P.
    Hillaire-Buys, D.
    Faillie, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 103 - 103
  • [29] Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study
    Yang, Hui
    Ding, Zhexin
    An, Zhuoling
    Zhao, Yong
    Lu, Hezhe
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [30] Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database
    Hu, Fangyuan
    Zhai, Yinghong
    Yuan, Lei
    Liang, Jizhou
    Xu, Jinfang
    Guo, Xiaojing
    Zhou, Xiang
    Lin, Zhen
    Sun, Jinhai
    Ye, Xiaofei
    He, Jia
    CANCER MEDICINE, 2021, 10 (24): : 8754 - 8762
12345